title: [The effect of paclitaxel-eluting stents on restenosis].
abstract: OBJECTIVE
  In our study we aimed to investigate the effects of paclitaxel-eluting stent on restenosis.
  
  
  METHODS
  Sixteen porcine were randomly assigned to two groups (n=8 per group): control group animals received conventional stent implantation and study group animals -paclitaxel-eluting stent implantation. Both groups were treated with 300 mg acetylsalicylic acid and 75 mg clopidogrel daily. The degree of neointimal proliferation and effect of drug-eluting stent on restenosis were evaluated 6 weeks after by angiography and intravascular ultrasound (IVUS).
  
  
  RESULTS
  Angiographic in-stent restenosis was lower in paclitaxel-eluting stent group (12.50 +/- 7.07% versus 41.25 +/- 28.50%, p=0.001). The IVUS data demonstrated that paclitaxel group animals had larger minimal lumen area (8.76 +/- 1.09 mm2 versus 6.23 +/- 3.10 mm2, p=0.028), smaller mean neointimal proliferation area (1.03 +/- 0.75 mm2 versus 3.55 +/- 2.86 mm2, p=0.01) and mean percent stenosis (10.71 +/- 8.10% versus 36.85 +/- 30.93%, p=0.01).
  
  
  CONCLUSIONS
  This study suggests that drug-eluting stents may also have a preventive effect for the in-stent restenosis.
authors.affiliation: Gülhane Askeri Tip Akademisi Kardiyoloji, Anabilim Dallari, Ankara, Türkiye.
authors.forename: Hürkan
authors.initials: H
authors.lastname: Kurşaklioğlu
authors.forename: Cem
authors.initials: C
authors.lastname: Köz
authors.forename: Atilla
authors.initials: A
authors.lastname: Iyisoy
authors.forename: Tayfun
authors.initials: T
authors.lastname: Ide
authors.forename: Vedat
authors.initials: V
authors.lastname: Yildirim
authors.forename: Hasan Fehmi
authors.initials: HF
authors.lastname: Töre
authors.forename: Ersoy
authors.initials: E
authors.lastname: Işik
authors.forename: Ertan
authors.initials: E
authors.lastname: Demirtaş
mesh_terms: D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003331:Coronary Vessels / Q000000981:diagnostic imaging; D004195:Disease Models, Animal; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011897:Random Allocation; D055502:Secondary Prevention; D015607:Stents; D013552:Swine; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017539:Tunica Intima / Q000473:pathology; D018084:Ultrasonography, Interventional / Q000379:methods*
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D017239:Paclitaxel; D001241:Aspirin